

# Harriet M Kluger

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4757133/publications.pdf>

Version: 2024-02-01

193  
papers

17,763  
citations

30070

54  
h-index

14759

127  
g-index

195  
all docs

195  
docs citations

195  
times ranked

23332  
citing authors

#	ARTICLE	IF	CITATIONS
1	Nivolumab plus Ipilimumab in Advanced Melanoma. <i>New England Journal of Medicine</i> , 2013, 369, 122-133.	27.0	3,776
2	Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab. <i>Journal of Clinical Oncology</i> , 2014, 32, 1020-1030.	1.6	2,015
3	Exome sequencing identifies recurrent somatic RAC1 mutations in melanoma. <i>Nature Genetics</i> , 2012, 44, 1006-1014.	21.4	1,052
4	Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial. <i>Lancet Oncology</i> , The, 2016, 17, 976-983.	10.7	846
5	Collateral Damage: Insulin-Dependent Diabetes Induced With Checkpoint Inhibitors. <i>Diabetes</i> , 2018, 67, 1471-1480.	0.6	386
6	Survival, Durable Response, and Long-Term Safety in Patients With Previously Treated Advanced Renal Cell Carcinoma Receiving Nivolumab. <i>Journal of Clinical Oncology</i> , 2015, 33, 2013-2020.	1.6	385
7	Combination Therapy with Anti-CTLA-4 and Anti-PD-1 Leads to Distinct Immunologic Changes In Vivo. <i>Journal of Immunology</i> , 2015, 194, 950-959.	0.8	362
8	Exome sequencing identifies recurrent mutations in NF1 and RASopathy genes in sun-exposed melanomas. <i>Nature Genetics</i> , 2015, 47, 996-1002.	21.4	348
9	Pembrolizumab for management of patients with NSCLC and brain metastases: long-term results and biomarker analysis from a non-randomised, open-label, phase 2 trial. <i>Lancet Oncology</i> , The, 2020, 21, 655-663.	10.7	335
10	Early B cell changes predict autoimmunity following combination immune checkpoint blockade. <i>Journal of Clinical Investigation</i> , 2018, 128, 715-720.	8.2	298
11	Radiosurgery for melanoma brain metastases in the ipilimumab era and the possibility of longer survival. <i>Journal of Neurosurgery</i> , 2012, 117, 227-233.	1.6	296
12	Precipitation of Autoimmune Diabetes With Anti-PD-1 Immunotherapy. <i>Diabetes Care</i> , 2015, 38, e55-e57.	8.6	278
13	Long-Term Survival of Patients With Melanoma With Active Brain Metastases Treated With Pembrolizumab on a Phase II Trial. <i>Journal of Clinical Oncology</i> , 2019, 37, 52-60.	1.6	218
14	Incidence of the V600K mutation among melanoma patients with BRAF mutations, and potential therapeutic response to the specific BRAF inhibitor PLX4032. <i>Journal of Translational Medicine</i> , 2010, 8, 67.	4.4	210
15	Characterization of PD-L1 Expression and Associated T-cell Infiltrates in Metastatic Melanoma Samples from Variable Anatomic Sites. <i>Clinical Cancer Research</i> , 2015, 21, 3052-3060.	7.0	198
16	Does immunotherapy increase the rate of radiation necrosis after radiosurgical treatment of brain metastases?. <i>Journal of Neurosurgery</i> , 2016, 125, 17-23.	1.6	192
17	Timing and type of immune checkpoint therapy affect the early radiographic response of melanoma brain metastases to stereotactic radiosurgery. <i>Cancer</i> , 2016, 122, 3051-3058.	4.1	182
18	A First-in-Human Study and Biomarker Analysis of NKTR-214, a Novel IL2R $\beta$ -Biased Cytokine, in Patients with Advanced or Metastatic Solid Tumors. <i>Cancer Discovery</i> , 2019, 9, 711-721.	9.4	180

#	ARTICLE	IF	CITATIONS
19	Bempegaldesleukin (NKTR-214) plus Nivolumab in Patients with Advanced Solid Tumors: Phase I Dose-Escalation Study of Safety, Efficacy, and Immune Activation (PIVOT-02). <i>Cancer Discovery</i> , 2020, 10, 1158-1173.	9.4	158
20	Nivolumab Plus Ipilimumab in Patients With Advanced Melanoma: Updated Survival, Response, and Safety Data in a Phase I Dose-Escalation Study. <i>Journal of Clinical Oncology</i> , 2018, 36, 391-398.	1.6	156
21	Lifileucel, a Tumor-Infiltrating Lymphocyte Therapy, in Metastatic Melanoma. <i>Journal of Clinical Oncology</i> , 2021, 39, 2656-2666.	1.6	145
22	Inflammatory eruptions associated with immune checkpoint inhibitor therapy: A single-institution retrospective analysis with stratification of reactions by toxicity and implications for management. <i>Journal of the American Academy of Dermatology</i> , 2019, 80, 990-997.	1.2	130
23	A phase 2 trial of dasatinib in advanced melanoma. <i>Cancer</i> , 2011, 117, 2202-2208.	4.1	129
24	Defining tumor resistance to PD-1 pathway blockade: recommendations from the first meeting of the SITC Immunotherapy Resistance Taskforce. , 2020, 8, e000398.		125
25	PD-L1 Studies Across Tumor Types, Its Differential Expression and Predictive Value in Patients Treated with Immune Checkpoint Inhibitors. <i>Clinical Cancer Research</i> , 2017, 23, 4270-4279.	7.0	117
26	High-Plex Predictive Marker Discovery for Melanoma Immunotherapyâ€”Treated Patients Using Digital Spatial Profiling. <i>Clinical Cancer Research</i> , 2019, 25, 5503-5512.	7.0	117
27	KDM5B promotes immune evasion by recruiting SETDB1 to silence retroelements. <i>Nature</i> , 2021, 598, 682-687.	27.8	117
28	Melanoma Brain Metastasis Pseudoprogression after Pembrolizumab Treatment. <i>Cancer Immunology Research</i> , 2016, 4, 179-182.	3.4	115
29	Analysis of multispectral imaging with the AstroPath platform informs efficacy of PD-1 blockade. <i>Science</i> , 2021, 372, .	12.6	114
30	Interlesional diversity of T cell receptors in melanoma with immune checkpoints enriched in tissue-resident memory T cells. <i>JCI Insight</i> , 2016, 1, e88955.	5.0	111
31	Multiplex Quantitative Analysis of Tumor-Infiltrating Lymphocytes and Immunotherapy Outcome in Metastatic Melanoma. <i>Clinical Cancer Research</i> , 2019, 25, 2442-2449.	7.0	106
32	Melanoma central nervous system metastases: current approaches, challenges, and opportunities. <i>Pigment Cell and Melanoma Research</i> , 2016, 29, 627-642.	3.3	102
33	Genomic characterization of sarcomatoid transformation in clear cell renal cell carcinoma. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016, 113, 2170-2175.	7.1	102
34	Macrophage Colony-Stimulating Factor-1 Receptor Expression Is Associated with Poor Outcome in Breast Cancer by Large Cohort Tissue Microarray Analysis. <i>Clinical Cancer Research</i> , 2004, 10, 173-177.	7.0	99
35	Evaluating the Expression and Prognostic Value of TRAIL-R1 and TRAIL-R2 in Breast Cancer. <i>Clinical Cancer Research</i> , 2005, 11, 5188-5194.	7.0	85
36	Chemotherapy and biologic therapies for melanoma: do they work?. <i>Clinics in Dermatology</i> , 2009, 27, 614-625.	1.6	83

#	ARTICLE	IF	CITATIONS
37	The X-linked inhibitor of apoptosis protein (XIAP) is up-regulated in metastatic melanoma, and XIAP cleavage by Phenoxodiol is associated with Carboplatin sensitization. <i>Journal of Translational Medicine</i> , 2007, 5, 6.	4.4	82
38	Plasma Markers for Identifying Patients with Metastatic Melanoma. <i>Clinical Cancer Research</i> , 2011, 17, 2417-2425.	7.0	80
39	Deep Learning Based on Standard H&E Images of Primary Melanoma Tumors Identifies Patients at Risk for Visceral Recurrence and Death. <i>Clinical Cancer Research</i> , 2020, 26, 1126-1134.	7.0	78
40	Vertical Targeting of the Phosphatidylinositol-3 Kinase Pathway as a Strategy for Treating Melanoma. <i>Clinical Cancer Research</i> , 2010, 16, 6029-6039.	7.0	77
41	Automated Quantitative Analysis of Tissue Microarrays Reveals an Association between High Bcl-2 Expression and Improved Outcome in Melanoma. <i>Cancer Research</i> , 2004, 64, 8773-8777.	0.9	75
42	Using a Xenograft Model of Human Breast Cancer Metastasis to Find Genes Associated with Clinically Aggressive Disease. <i>Cancer Research</i> , 2005, 65, 5578-5587.	0.9	73
43	Role of Chitinase 3-like-1 and Semaphorin 7a in Pulmonary Melanoma Metastasis. <i>Cancer Research</i> , 2015, 75, 487-496.	0.9	71
44	PLEKHA5 as a Biomarker and Potential Mediator of Melanoma Brain Metastasis. <i>Clinical Cancer Research</i> , 2015, 21, 2138-2147.	7.0	71
45	Safety and efficacy of cryopreserved autologous tumor infiltrating lymphocyte therapy (LN-144), Tj ETQq1 1 0.784314 rgBT /Overlock including anti-PD-1.. <i>Journal of Clinical Oncology</i> , 2019, 37, 2518-2518.	1.6	71
46	cDNA microarray analysis of invasive and tumorigenic phenotypes in a breast cancer model. <i>Laboratory Investigation</i> , 2004, 84, 320-331.	3.7	66
47	Systemic Immunotherapy for the Treatment of Brain Metastases. <i>Frontiers in Oncology</i> , 2016, 6, 49.	2.8	66
48	?B-crystallin as a marker of lymph node involvement in breast carcinoma. <i>Cancer</i> , 2004, 100, 2543-2548.	4.1	65
49	Long-term survival of ipilimumab-naïve patients (pts) with advanced melanoma (MEL) treated with nivolumab (anti-PD-1, BMS-936558, ONO-4538) in a phase I trial.. <i>Journal of Clinical Oncology</i> , 2014, 32, 9002-9002.	1.6	64
50	Patterns of failure after immunotherapy with checkpoint inhibitors predict durable progression-free survival after local therapy for metastatic melanoma. , 2019, 7, 196.		62
51	MEK targeting in N-RAS mutated metastatic melanoma. <i>Molecular Cancer</i> , 2014, 13, 45.	19.2	61
52	A Serum Protein Signature Associated with Outcome after Anti-PD-1 Therapy in Metastatic Melanoma. <i>Cancer Immunology Research</i> , 2018, 6, 79-86.	3.4	61
53	Automated Quantitative Analysis of HDM2 Expression in Malignant Melanoma Shows Association with Early-Stage Disease and Improved Outcome. <i>Cancer Research</i> , 2004, 64, 8767-8772.	0.9	60
54	Phosphatidylinositol-3-Kinase as a Therapeutic Target in Melanoma. <i>Clinical Cancer Research</i> , 2009, 15, 3029-3036.	7.0	59

#	ARTICLE	IF	CITATIONS
55	Melanoma: Clinical Presentations. <i>Cancer Treatment and Research</i> , 2016, 167, 107-129.	0.5	59
56	Phase II randomised discontinuation trial of the MET/VEGF receptor inhibitor cabozantinib in metastatic melanoma. <i>British Journal of Cancer</i> , 2017, 116, 432-440.	6.4	59
57	Intratumour microbiome associated with the infiltration of cytotoxic CD8+ T cells and patient survival in cutaneous melanoma. <i>European Journal of Cancer</i> , 2021, 151, 25-34.	2.8	59
58	Stereotactic radiosurgery of early melanoma brain metastases after initiation of anti-CTLA-4 treatment is associated with improved intracranial control. <i>Radiotherapy and Oncology</i> , 2017, 125, 80-88.	0.6	58
59	B cell depletion or absence does not impede anti-tumor activity of PD-1 inhibitors. , 2019, 7, 153.		58
60	Driver Mutations in Melanoma: Lessons Learned From Bench-to-Bedside Studies. <i>Current Oncology Reports</i> , 2012, 14, 449-457.	4.0	56
61	A phase III randomized study of adjuvant ipilimumab (3 or 10 mg/kg) versus high-dose interferon alfa-2b for resected high-risk melanoma (U.S. Intergroup E1609): Preliminary safety and efficacy of the ipilimumab arms.. <i>Journal of Clinical Oncology</i> , 2017, 35, 9500-9500.	1.6	56
62	Expression patterns and prognostic value of Bag-1 and Bcl-2 in breast cancer. <i>Breast Cancer Research</i> , 2008, 10, R35.	5.0	53
63	Treatment-Free Survival: A Novel Outcome Measure of the Effects of Immune Checkpoint Inhibitionâ€”A Pooled Analysis of Patients With Advanced Melanoma. <i>Journal of Clinical Oncology</i> , 2019, 37, 3350-3358.	1.6	52
64	Increased Expression of the E3 Ubiquitin Ligase RNF5 Is Associated with Decreased Survival in Breast Cancer. <i>Cancer Research</i> , 2007, 67, 8172-8179.	0.9	51
65	Agonistic CD40 Antibodies in Cancer Treatment. <i>Cancers</i> , 2021, 13, 1302.	3.7	50
66	Automated Quantitative Analysis of E-Cadherin Expression in Lymph Node Metastases Is Predictive of Survival in Invasive Ductal Breast Cancer. <i>Clinical Cancer Research</i> , 2005, 11, 4083-4089.	7.0	49
67	Possible Interaction of Antiâ€”PD-1 Therapy with the Effects of Radiosurgery on Brain Metastases. <i>Cancer Immunology Research</i> , 2016, 4, 481-487.	3.4	49
68	Transcriptomic Hallmarks of Tumor Plasticity and Stromal Interactions in Brain Metastasis. <i>Cell Reports</i> , 2019, 27, 1277-1292.e7.	6.4	49
69	Characterization of tumor infiltrating lymphocytes in paired primary and metastatic renal cell carcinoma specimens. <i>Oncotarget</i> , 2015, 6, 24990-25002.	1.8	49
70	PAX-8 expression in renal tumours and distant sites: A useful marker of primary and metastatic renal cell carcinoma?. <i>Journal of Clinical Pathology</i> , 2015, 68, 12-17.	2.0	48
71	Survival after checkpoint inhibitors for metastatic acral, mucosal and uveal melanoma. , 2020, 8, e000341.		48
72	Circulating clonally expanded T cells reflect functions of tumor-infiltrating T cells. <i>Journal of Experimental Medicine</i> , 2021, 218, .	8.5	48

#	ARTICLE	IF	CITATIONS
73	Classification of renal cell carcinoma based on expression of VEGF and VEGF receptors in both tumor cells and endothelial cells. <i>Laboratory Investigation</i> , 2008, 88, 962-972.	3.7	47
74	Multiplex quantitative analysis of cancer-associated fibroblasts and immunotherapy outcome in metastatic melanoma. , 2019, 7, 194.		47
75	The transcription factor ATF2 promotes melanoma metastasis by suppressing protein fucosylation. <i>Science Signaling</i> , 2015, 8, ra124.	3.6	46
76	Toxicity and Activity of a Twice Daily High-dose Bolus Interleukin 2 Regimen in Patients With Metastatic Melanoma and Metastatic Renal Cell Cancer. <i>Journal of Immunotherapy</i> , 2008, 31, 569-576.	2.4	44
77	A Phase I Study of APX005M and Cabiralizumab with or without Nivolumab in Patients with Melanoma, Kidney Cancer, or Non-small Cell Lung Cancer Resistant to Anti-PD-1/PD-L1. <i>Clinical Cancer Research</i> , 2021, 27, 4757-4767.	7.0	44
78	Ophthalmic Immune-Related Adverse Events of Immunotherapy: A Single-Site Case Series. <i>Ophthalmology</i> , 2019, 126, 1058-1062.	5.2	43
79	Renalase Expression by Melanoma and Tumor-Associated Macrophages Promotes Tumor Growth through a STAT3-Mediated Mechanism. <i>Cancer Research</i> , 2016, 76, 3884-3894.	0.9	41
80	Her2/neu is not a commonly expressed therapeutic target in melanoma – a large cohort tissue microarray study. <i>Melanoma Research</i> , 2004, 14, 207-210.	1.2	39
81	Comparing available criteria for measuring brain metastasis response to immunotherapy. <i>Journal of Neuro-Oncology</i> , 2017, 132, 479-485.	2.9	39
82	Expression of Sorafenib Targets in Melanoma Patients Treated with Carboplatin, Paclitaxel and Sorafenib. <i>Clinical Cancer Research</i> , 2009, 15, 1076-1085.	7.0	38
83	Copy Number Changes Are Associated with Response to Treatment with Carboplatin, Paclitaxel, and Sorafenib in Melanoma. <i>Clinical Cancer Research</i> , 2016, 22, 374-382.	7.0	38
84	Biomarker Discovery in Patients with Immunotherapy-Treated Melanoma with Imaging Mass Cytometry. <i>Clinical Cancer Research</i> , 2021, 27, 1987-1996.	7.0	38
85	C-Raf Is Associated with Disease Progression and Cell Proliferation in a Subset of Melanomas. <i>Clinical Cancer Research</i> , 2009, 15, 5704-5713.	7.0	37
86	Advances in therapy for melanoma brain metastases. <i>Clinics in Dermatology</i> , 2013, 31, 264-281.	1.6	36
87	Identification of Novel Radiosensitizers in a High-Throughput, Cell-Based Screen for DSB Repair Inhibitors. <i>Molecular Cancer Therapeutics</i> , 2015, 14, 326-342.	4.1	36
88	Brain Metastasis From Renal-Cell Carcinoma: An Institutional Study. <i>Clinical Genitourinary Cancer</i> , 2019, 17, e1163-e1170.	1.9	36
89	Leptomeningeal disease in melanoma patients: An update to treatment, challenges, and future directions. <i>Pigment Cell and Melanoma Research</i> , 2020, 33, 527-541.	3.3	36
90	SHARPIN-mediated regulation of protein arginine methyltransferase 5 controls melanoma growth. <i>Journal of Clinical Investigation</i> , 2017, 128, 517-530.	8.2	36

#	ARTICLE	IF	CITATIONS
91	Nuclear IRF-1 expression as a mechanism to assess "Capability" to express PD-L1 and response to PD-1 therapy in metastatic melanoma. , 2017, 5, 25.		35
92	Merkel cell polyomavirus-specific immune responses in patients with Merkel cell carcinoma receiving anti-PD-1 therapy. , 2018, 6, 131.		35
93	Expression of Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand Receptors 1 and 2 in Melanoma. <i>Clinical Cancer Research</i> , 2006, 12, 3856-3863.	7.0	34
94	Melanoma Brain Metastases: Is It Time to Reassess the Bias?. <i>Current Problems in Cancer</i> , 2011, 35, 200-210.	2.0	33
95	Correlation of Somatic Mutations and Clinical Outcome in Melanoma Patients Treated with Carboplatin, Paclitaxel, and Sorafenib. <i>Clinical Cancer Research</i> , 2014, 20, 3328-3337.	7.0	33
96	Clinicopathological and immunohistochemical characteristics of papillary renal cell carcinoma with emphasis on subtyping. <i>Human Pathology</i> , 2015, 46, 1418-1426.	2.0	33
97	Durability of brain metastasis response and overall survival in patients with non-small cell lung cancer (NSCLC) treated with pembrolizumab.. <i>Journal of Clinical Oncology</i> , 2018, 36, 2009-2009.	1.6	33
98	Long-term follow up of lifileucel (LN-144) cryopreserved autologous tumor infiltrating lymphocyte therapy in patients with advanced melanoma progressed on multiple prior therapies.. <i>Journal of Clinical Oncology</i> , 2020, 38, 10006-10006.	1.6	32
99	FRACTION-RCC: Innovative, high-throughput assessment of nivolumab + ipilimumab for treatment-refractory advanced renal cell carcinoma (aRCC).. <i>Journal of Clinical Oncology</i> , 2020, 38, 5007-5007.	1.6	28
100	Complications associated with immunotherapy for brain metastases. <i>Current Opinion in Neurology</i> , 2019, 32, 907-916.	3.6	27
101	Adverse events induced by immune checkpoint inhibitors. <i>Current Opinion in Immunology</i> , 2021, 69, 29-38.	5.5	25
102	Immune Checkpoint Inhibitor-Induced Hypophysitis and Patterns of Loss of Pituitary Function. <i>Frontiers in Oncology</i> , 2022, 12, 836859.	2.8	25
103	Evolving Immunotherapy Approaches for Renal Cell Carcinoma. <i>Current Oncology Reports</i> , 2016, 18, 57.	4.0	24
104	Anti-PD-1 Therapy-Associated Perforating Colitis. <i>Case Reports in Gastrointestinal Medicine</i> , 2018, 2018, 1-3.	0.3	24
105	High WHO/ISUP Grade and Unfavorable Architecture, Rather Than Typing of Papillary Renal Cell Carcinoma, May Be Associated With Worse Prognosis. <i>American Journal of Surgical Pathology</i> , 2020, 44, 582-593.	3.7	24
106	Activity and safety of pembrolizumab in patients with metastatic non-small cell lung cancer with untreated brain metastases.. <i>Journal of Clinical Oncology</i> , 2015, 33, 8035-8035.	1.6	24
107	MET Inhibition in Clear Cell Renal Cell Carcinoma. <i>Journal of Cancer</i> , 2016, 7, 1205-1214.	2.5	23
108	Tumor Microvessel Density as a Prognostic Marker in High-Risk Renal Cell Carcinoma Patients Treated on ECOG-ACRIN E2805. <i>Clinical Cancer Research</i> , 2018, 24, 217-223.	7.0	23

#	ARTICLE	IF	CITATIONS
109	Perilesional edema in brain metastases: potential causes and implications for treatment with immune therapy. , 2019, 7, 200.		23
110	Safety and activity of pembrolizumab in melanoma patients with untreated brain metastases.. Journal of Clinical Oncology, 2015, 33, 9009-9009.	1.6	22
111	Automated digital TIL analysis (ADTA) adds prognostic value to standard assessment of depth and ulceration in primary melanoma. Scientific Reports, 2021, 11, 2809.	3.3	20
112	Safety and clinical activity of nivolumab (anti-PD-1, BMS-936558, ONO-4538) in combination with ipilimumab in patients (pts) with advanced melanoma (MEL).. Journal of Clinical Oncology, 2013, 31, 9012-9012.	1.6	20
113	Baseline tumor-immune signatures associated with response to bempedgesleukin (NKTR-214) and nivolumab.. Journal of Clinical Oncology, 2019, 37, 2623-2623.	1.6	20
114	TCR-sequencing in cancer and autoimmunity: barcodes and beyond. Trends in Immunology, 2022, 43, 180-194.	6.8	20
115	Left ventricular myocardial strain and tissue characterization by cardiac magnetic resonance imaging in immune checkpoint inhibitor associated cardiotoxicity. PLoS ONE, 2021, 16, e0246764.	2.5	19
116	Effect of a novel IL-2 cytokine immune agonist (NKTR-214) on proliferating CD8+T cells and PD-1 expression on immune cells in the tumor microenvironment in patients with prior checkpoint therapy.. Journal of Clinical Oncology, 2017, 35, 2545-2545.	1.6	19
117	Mortality after acute kidney injury and acute interstitial nephritis in patients prescribed immune checkpoint inhibitor therapy. , 2022, 10, e004421.		19
118	Quantitative analysis of CMTM6 expression in tumor microenvironment in metastatic melanoma and association with outcome on immunotherapy. Oncoimmunology, 2021, 10, 1864909.	4.6	18
119	Ipilimumab: a promising immunotherapy for melanoma. Oncology, 2010, 24, 1280-8.	0.5	17
120	The Treatment of Melanoma Brain Metastases. Current Oncology Reports, 2016, 18, 73.	4.0	16
121	Benefits of biomarker selection and clinico-pathological covariate inclusion in breast cancer prognostic models. Breast Cancer Research, 2010, 12, R66.	5.0	15
122	Expression of drug targets in primary and matched metastatic renal cell carcinoma tumors. BMC Clinical Pathology, 2013, 13, 3.	1.8	15
123	Melanoma brain metastases have lower T-cell content and microvessel density compared to matched extracranial metastases. Journal of Neuro-Oncology, 2021, 152, 15-25.	2.9	15
124	Clinical results with combination of anti-CD27 agonist antibody, varlilumab, with anti-PD1 antibody nivolumab in advanced cancer patients.. Journal of Clinical Oncology, 2017, 35, 3007-3007.	1.6	15
125	United States Intergroup E1609: A phase III randomized study of adjuvant ipilimumab (3 or 10 mg/kg) versus high-dose interferon- $\gamma$ 2b for resected high-risk melanoma.. Journal of Clinical Oncology, 2019, 37, 9504-9504.	1.6	15
126	Immunotherapy for metastatic melanoma. Journal of Cellular Biochemistry, 2012, 113, 725-734.	2.6	14



#	ARTICLE	IF	CITATIONS
127	Closed system RT-qPCR as a potential companion diagnostic test for immunotherapy outcome in metastatic melanoma. , 2019, 7, 254.		14
128	Frequent Use of Local Therapy Underscores Need for Multidisciplinary Care in the Management of Patients With Melanoma Brain Metastases Treated With PD-1 Inhibitors. International Journal of Radiation Oncology Biology Physics, 2019, 105, 1113-1118.	0.8	14
129	Regulation of eIF2 $\gamma$ by RNF4 Promotes Melanoma Tumorigenesis and Therapy Resistance. Journal of Investigative Dermatology, 2020, 140, 2466-2477.	0.7	13
130	Immune adverse events (irAEs) with adjuvant ipilimumab in melanoma, use of immunosuppressants and association with outcome: ECOG-ACRIN E1609 study analysis. , 2021, 9, e002535.		13
131	In vitro studies of dasatinib, its targets and predictors of sensitivity. Pigment Cell and Melanoma Research, 2011, 24, 386-389.	3.3	12
132	PLEKHA5 regulates tumor growth in metastatic melanoma. Cancer, 2020, 126, 1016-1030.	4.1	12
133	[ <sup>11</sup> C]Methionine and [ <sup>11</sup> C]PBR28 as PET Imaging Tracers to Differentiate Metastatic Tumor Recurrence or Radiation Necrosis. Molecular Imaging, 2020, 19, 153601212096866.	1.4	12
134	A phase 1/2 study of a novel IL-2 cytokine, NKTR-214, and nivolumab in patients with select locally advanced or metastatic solid tumors.. Journal of Clinical Oncology, 2017, 35, e14040-e14040.	1.6	12
135	Genomic Heterogeneity and the Small Renal Mass. Clinical Cancer Research, 2018, 24, 4137-4144.	7.0	11
136	Models that combine transcriptomic with spatial protein information exceed the predictive value for either single modality. Npj Precision Oncology, 2021, 5, 45.	5.4	11
137	Outcomes of Stereotactic Radiosurgery and Immunotherapy in Renal Cell Carcinoma Patients With Brain Metastases. American Journal of Clinical Oncology: Cancer Clinical Trials, 2021, 44, 495-501.	1.3	11
138	Clinical trials in melanoma patients with brain metastases. Pigment Cell and Melanoma Research, 2015, 28, 741-743.	3.3	10
139	Incidence and characteristics of metastatic intracranial lesions in stage III and IV melanoma: a single institute retrospective analysis. Journal of Neuro-Oncology, 2021, 154, 197-203.	2.9	10
140	Central Nervous System Metastases. Hematology/Oncology Clinics of North America, 2022, 36, 161-188.	2.2	10
141	Autoimmune retinopathy with associated anti-retinal antibodies as a potential immune-related adverse event associated with immunotherapy in patients with advanced cutaneous melanoma: case series and systematic review. BMJ Open Ophthalmology, 2022, 7, e000889.	1.6	10
142	Apoptosis: a clinical perspective. Nature Reviews Drug Discovery, 2008, 7, 959-959.	46.4	9
143	Molecular Alternations in Uveal Melanoma. Current Problems in Cancer, 2011, 35, 211-224.	2.0	9
144	Radiation sensitivity and sensitization in melanoma. Pigment Cell and Melanoma Research, 2013, 26, 928-930.	3.3	9

#	ARTICLE	IF	CITATIONS
145	Clinical Significance of PDCD4 in Melanoma by Subcellular Expression and in Tumor-Associated Immune Cells. <i>Cancers</i> , 2021, 13, 1049.	3.7	9
146	Phase I study of safety and tolerability of sunitinib in combination with sirolimus in patients with refractory solid malignancies and determination of VEGF (VEGF-A) and soluble VEGF-R2 (sVEGFR2) in plasma. <i>Cancer Chemotherapy and Pharmacology</i> , 2016, 77, 1193-1200.	2.3	8
147	Neoadjuvant anti-“programmed cell death 1 therapy for locally advanced basal cell carcinoma in treatment-naïve patients: A case series. <i>JAAD Case Reports</i> , 2020, 6, 628-633.	0.8	8
148	Efficacy of single administration of tumor-infiltrating lymphocytes (TIL) in heavily pretreated patients with metastatic melanoma following checkpoint therapy.. <i>Journal of Clinical Oncology</i> , 2017, 35, 3045-3045.	1.6	8
149	CheckMate-067: Raising the Bar for the Next Decade in Oncology. <i>Journal of Clinical Oncology</i> , 2022, 40, 111-113.	1.6	8
150	Spatially resolved analysis of the T cell immune contexture in lung cancer-associated brain metastases. , 2021, 9, e002684.		8
151	Microvessel area as a predictor of sorafenib response in metastatic renal cell carcinoma. <i>Cancer Cell International</i> , 2014, 14, 4.	4.1	6
152	MET Expression in Primary and Metastatic Clear Cell Renal Cell Carcinoma: Implications of Correlative Biomarker Assessment to MET Pathway Inhibitors. <i>BioMed Research International</i> , 2015, 2015, 1-7.	1.9	6
153	Coupled fibromodulin and SOX2 signaling as a critical regulator of metastatic outgrowth in melanoma. <i>Cellular and Molecular Life Sciences</i> , 2022, 79, .	5.4	6
154	Association Between Food and Drug Administration Approval and Disparities in Immunotherapy Use Among Patients With Cancer in the US. <i>JAMA Network Open</i> , 2022, 5, e2219535.	5.9	6
155	Phase 2 study of cobimetinib in combination with vemurafenib in active melanoma brain metastases (coBRIM-B).. <i>Journal of Clinical Oncology</i> , 2015, 33, TPS9088-TPS9088.	1.6	5
156	A phase I, open-label, multicenter, single-dose escalation and multi-dose study of a monoclonal antibody targeting CEACAM1 in subjects with selected advanced or recurrent malignancies.. <i>Journal of Clinical Oncology</i> , 2020, 38, 3094-3094.	1.6	5
157	Emerging Studies of Melanoma Brain Metastasis. <i>Current Oncology Reports</i> , 2022, 24, 585-594.	4.0	5
158	Primary Treatment Selection for Clinically Node-“Negative Merkel Cell Carcinoma of the Head and Neck. <i>Otolaryngology - Head and Neck Surgery</i> , 2021, 164, 1214-1221.	1.9	4
159	A phase 1b study of nivolumab in patients with autoimmune disorders and advanced malignancies (AIM-NIVO).. <i>Journal of Clinical Oncology</i> , 2021, 39, TPS2676-TPS2676.	1.6	4
160	Merkel Cell Carcinoma: Changing Practice Patterns and Impact on Recurrence-Free and Overall Survival at a Single Institution and Nationally. <i>Annals of Surgical Oncology</i> , 2022, 29, 415-424.	1.5	4
161	Microvessel density as a prognostic marker in high-risk renal cell carcinoma.. <i>Journal of Clinical Oncology</i> , 2017, 35, 4565-4565.	1.6	4
162	Evaluating the role of the COX2/PGE2 pathway in anti-melanoma immunity.. <i>Journal of Clinical Oncology</i> , 2019, 37, e14114-e14114.	1.6	4

#	ARTICLE	IF	CITATIONS
163	Drug targets and predictive biomarkers in the management of metastatic melanoma. Pharmacogenomics and Personalized Medicine, 2012, 5, 139.	0.7	3
164	P865â€¦Safety & efficacy of lifileucel (LN-144) tumor infiltrating lymphocyte therapy in metastatic melanoma patients after progression on multiple therapies â€œ independent review committee data update. , 2020, , .		3
165	Autologous genetically engineered NY-ESO-1 <sup>c259</sup>T in HLA-A*02:01, HLA*02:05 and HLA*02:06 positive patients with NY-ESO-1 expressing tumors.. Journal of Clinical Oncology, 2016, 34, TPS3101-TPS3101.	1.6	3
166	Expression of Drug Targets in Patients Treated with Sorafenib, Carboplatin and Paclitaxel. PLoS ONE, 2013, 8, e69748.	2.5	3
167	NY-ESO-1 as a potential immunotherapeutic target in renal cell carcinoma. Oncotarget, 2014, 5, 5209-5217.	1.8	3
168	Advances in the systemic treatment of metastatic melanoma. Oncology, 2013, 27, 374-81.	0.5	3
169	ASO Visual Abstract: Merkel Cell Carcinomaâ€”Changing Practice Patterns and Impact on Recurrence-Free and Overall Survival at a Single Institution and Nationally. Annals of Surgical Oncology, 2021, 28, 736-737.	1.5	2
170	Long-term follow-up of CA209-004: A phase I dose-escalation study of combined nivolumab (NIVO) and ipilimumab (IPI) in patients with advanced melanoma.. Journal of Clinical Oncology, 2019, 37, 9533-9533.	1.6	2
171	Assessing Expression of Apoptotic Markers Using Large Cohort Tissue Microarrays. , 2008, 414, 83-93.		2
172	A phase Ib study of nivolumab in patients with autoimmune disorders and advanced malignancies (AIM-NIVO).. Journal of Clinical Oncology, 2020, 38, TPS3158-TPS3158.	1.6	2
173	Inhibition of renalase drives tumour rejection by promoting T cell activation. European Journal of Cancer, 2022, 165, 81-96.	2.8	2
174	Tumor mutational burden (TMB) in immune checkpoint inhibitor (ICI)-naïve and -experienced patients with metastatic melanoma treated with lifileucel, a tumor-infiltrating lymphocyte (TIL) cell therapy.. Journal of Clinical Oncology, 2022, 40, 9524-9524.	1.6	2
175	Targeting Innate Immunity to Treat Cancer. Cancers, 2020, 12, 2723.	3.7	1
176	Lenvatinib (len) plus pembrolizumab (pembro) in patients (pts) with advanced melanoma previously exposed to antiâ€œPD-1/PD-L1 agents: Phase 2 LEAP-004 study.. Journal of Clinical Oncology, 2019, 37, TPS9594-TPS9594.	1.6	1
177	Demonstration of differential radiosensitivity based upon mutation profile in metastatic melanoma treated with stereotactic radiosurgery. Journal of Radiosurgery and SBRT, 2016, 4, 97-106.	0.2	1
178	Mycophenolate as Primary Treatment for Immune Checkpoint Inhibitor Induced Acute Kidney Injury in a Patient with Concurrent Immunotherapy-Associated Diabetes: A Case Report. , 2021, 4, .		1
179	Reply to A. Shinde et al. Journal of Clinical Oncology, 2019, 37, 1031-1032.	1.6	0
180	19. PLEKHA5 REGULATES TUMOR GROWTH IN METASTATIC MELANOMA. Neuro-Oncology Advances, 2020, 2, ii3-ii3.	0.7	0

#	ARTICLE	IF	CITATIONS
181	Abstract 489: Association between immune-mediated adverse events and survival in patients with metastatic non-small cell lung cancer treated with durvalumab and tremelimumab. , 2021, , .		0
182	Adverse Histopathologic Characteristics in Small Papillary Renal Cell Carcinomas Have Minimal Impact on Prognosis. American Journal of Clinical Pathology, 2021, 156, 550-558.	0.7	0
183	Genomic characterization of sarcomatoid transformation in clear cell renal cell carcinoma.. Journal of Clinical Oncology, 2016, 34, 509-509.	1.6	0
184	Safety and feasibility of immuno-cryotherapy.. Journal of Clinical Oncology, 2018, 36, 34-34.	1.6	0
185	Melanoma Brain Metastases: Unique Biology and Implications for Systemic Therapy. , 2019, , 1-34.		0
186	Functional profile and clinical significance of major tumor infiltrating lymphocyte subsets in lung cancer-associated brain metastases.. Journal of Clinical Oncology, 2019, 37, 2066-2066.	1.6	0
187	Melanoma Brain Metastases: Unique Biology and Implications for Systemic Therapy. , 2020, , 1421-1454.		0
188	Cardiac Biventricular Metastasis From Renal Cell Carcinoma. Cureus, 2020, 12, e10870.	0.5	0
189	Elective Colectomy in a Patient with Active Ulcerative Colitis and Metastatic Melanoma Enabling Successful Treatment with Immune Checkpoint Inhibitors. , 2020, 3, .		0
190	Prolonged Complete Response of Early Stage Primary Adenocarcinoma of the Lung to Nivolumab Monotherapy. , 2021, 4, .		0
191	Reply to T. Olivier et al. Journal of Clinical Oncology, 2022, , JCO2200209.	1.6	0
192	Association between pathways in regulatory networks. Annual International Conference of the IEEE Engineering in Medicine and Biology Society, 2006, , .	0.5	0
193	Clinical predictors of longer survival in patients with BRAF<sup>V600</sup>-mutated metastatic melanoma receiving immunotherapy prior to BRAF/MEK inhibition in the metastatic setting.. Journal of Clinical Oncology, 2022, 40, 9555-9555.	1.6	0